ClinicalTrials.gg
RecruitingNCT07262190Philly NavSTARUpdated Dec 3, 2025

NavSTAR Implementation Effectiveness Trial Across a Health System

An interventional study of NavSTAR (Philly adaptation) in Opioid Use Disorder, sponsored by Friends Research Institute, Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-03.

Sponsored by Friends Research Institute, Inc. · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
720
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Opioid-Related Disorders by Friends Research Institute, Inc. — 4 open to participants now, 7 under way, 3 of them phase 3. Opioid-Related Disorders · Friends Research Institute, Inc..

Planned enrollment
Largest of 20
720 · median 235
Started
2025
with 4 others
No phase
11 of 20
3 open now
Registered
18th of 20
by date

Among the 20 studies in Opioid-Related Disorders by Friends Research Institute, Inc., this one has the largest planned enrollment, is one of 5 that started in 2025, is one of 11 with no phase, and was the 18th registered.

Opioid-Related Disorders

1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.

Browse Opioid-Related Disorders studies →

Open to participants now

4 of the 20 studies in Opioid-Related Disorders by Friends Research Institute, Inc. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Opioid-Related Disorders by Friends Research Institute, Inc., or all of them as a file.
02

Study summary

Patient Navigation (PN) interventions following hospitalization can improve outcomes for people with opioid use disorder treatment. Delivering PN interventions on a wide scale requires many resources and coordination across institutions. This will use an evidence-based process to find solutions to these significant barriers by engaging community, hospital, and patient partners. This study is being conducted to learn more about how to implement NavSTAR, a patient navigation intervention for people with opioid use disorder, across a health system. The research team showed in a previous study with 400 participants that NavSTAR significantly increased entry into opioid use disorder treatment, reduced readmissions to the hospital, and was highly cost- effective compared to treatment as usual. This study will first pilot NavSTAR with 32 patient participants across 4 hospitals in the City of Philadelphia. Then, a large trial with 720 patient participants will be conducted to see if people who need the intervention are reached, and a sustainable plan will be created to continue the intervention after the grant award period.

Read the detailed description

Opioid agonist treatment (OAT) is protective against overdose, yet less than 20% of people with opioid use disorder (OUD) engage in such treatment. Hospital utilization is high among people with OUD and can be a 'reachable moment' to initiate OAT. However, most hospitals lack the capacity to follow up with patients after discharge. Patient navigation (PN) interventions following hospital discharge can help patients engage in OAT and navigate complex systems of care. However, challenges persist in implementing PN interventions on a wide scale, as they require coordination across organizations, data sharing, dedicated personnel, and resources. To bring these interventions to scale, strategies are needed to determine feasibility, reach, and sustainability. Testing innovative implementation strategies for PN interventions has the potential for significant impact, as it will demonstrate implementation success of an intervention that can address the opioid epidemic in real-world settings and close the research-to-practice translation gap. The proposed study is a type II hybrid implementation-effectiveness trial of Navigation Services to Avoid Rehospitalization (NavSTAR). The research team showed in a single-site randomized trial with 400 participants that NavSTAR significantly improved OAT entry, reduced readmissions, and was highly cost-effective compared to treatment as usual. The present study will test an Implementation Facilitation (IF) strategy to provide training, resources, and performance feedback to implement NavSTAR in five hospitals in Philadelphia. It is hypothesized that engaging stakeholders in an IF strategy will yield an implementation process that is feasible, acceptable, and effective in improving outcomes for patients with OUD. During the R33 phase, a type II hybrid-implementation-effectiveness trial of NavSTAR will be conducted with 720 participants using a randomized stepped-wedge design.

The proposed study is a type II hybrid implementation-effectiveness trial of Navigation Services to Avoid Rehospitalization (NavSTAR). The present study will test an Implementation Facilitation (IF) strategy following Proctor's conceptual model of implementation, using an external facilitator and internal local clinical champions to provide training, resources and performance feedback to implement NavSTAR in five hospitals. It is hypothesized that engaging stakeholders in an IF strategy will yield an implementation process that is feasible, acceptable, and effective in expanding engagement in OAT post-discharge. This type II hybrid implementation-effectiveness randomized stepped-wedge trial (N=720) will examine NavSTAR's sustained use in a hospital system to improve outcomes for patients with OUD.

R33 Specific Aims:

  • Aim 1: Determine the successful implementation of NavSTAR in terms of a) feasibility, b) reach, and c) sustainability using the newly developed hospital system protocol.
  • Aim 2: Determine the effectiveness of NavSTAR to a) improve OAT initiation in the three months post-discharge, b) decrease hospital utilization (inpatient readmissions and emergency department visits), c) reduce overdoses (fatal and non-fatal), and d) improve other patient outcomes (e.g., quality of life, substance use).

The proposed study has high public health significance because it will develop and test an implementation strategy for an intervention (NavSTAR) to improve OAT engagement and outcomes for patients with OUD. The study will yield novel data on how best to implement NavSTAR across a health system operating in an epicenter of the OUD crisis. Study findings will help to develop a path to scale-up this important intervention to address the opioid epidemic.

03

Conditions studied

  • Opioid Use Disorder

Keywords

  • patient navigation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. age 18 or older;
  2. current criteria for moderate to severe OUD;
  3. willing and able to provide in English.

Exclusion criteria

Exclusion Criteria:

  1. enrollment in OUD treatment 30-days prior to hospitalization;
  2. residency outside the City of Philadelphia;
  3. pregnancy;
  4. planned discharge to a long-term inpatient care facility (e.g., hospice);
  5. hospitalization for a suicide attempt.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
720 participants (estimated)

Study arms

  • No intervention
    Treatment as Usual

    Treatment as usual consists of standard management by the medical or surgical team during inpatient admission, and usual care from the addiction consult service, if applicable, which provides social work consults, withdrawal symptom management, and initiation of naltrexone, buprenorphine, or methadone. All standard hospital services will be available to participants.

  • Experimental
    NavSTAR

    NavSTAR consists of TAU plus contact with a trained patient navigator who delivers the NavSTAR intervention, inclusive of theory-based motivational content, during and after discharge from the hospital. The patient navigator also has access to a small participant fund to assist with overcoming structural barriers to care (e.g., phone, obtaining IDs, a meal, a taxi ride etc.). Using the NavSTAR PN manual, the PN will address internal and external barriers to engagement in OAT through motivational intervention techniques and proactive case management and care coordination services. Contact with the PN begins at the bedside while the participant is admitted to the hospital and continues for 3 months after discharge

    Behavioral: NavSTAR (Philly adaptation)

Interventions

  • BehavioralNavSTAR (Philly adaptation)

    NavSTAR consists of TAU plus contact with a trained patient navigator who delivers the NavSTAR intervention, inclusive of theory-based motivational content, during and after discharge from the hospital. The patient navigator also has access to a small participant fund to assist with overcoming structural barriers to care (e.g., phone, obtaining IDs, a meal, a taxi ride etc.). Using the NavSTAR PN manual, the PN will address internal and external barriers to engagement in OAT through motivational intervention techniques and proactive case management and care coordination services. Contact with the PN begins at the bedside while the participant is admitted to the hospital and continues for 3 months after discharge

06

What researchers measure

Primary outcomes

  1. Rate of Opioid Agonist Treatment initiation

    Post-discharge rate of OAT initiation will be ascertained via health record review and self-report with verification through records where applicable (e.g., Community Behavioral Health system).

    Time frame: 3 months

Secondary outcomes

  1. Feasibility: Demonstrated ability to enroll participants in the intervention

    Feasibility will be measured based on the number of participants who received the intervention during the implementation period.

    Time frame: From baseline until end of study, approximately 30 months

  2. Inpatient readmissions (30 days)

    Information on acute care hospital inpatient readmission within 30 days will be assessed using health records and self-report (in the event of inconsistency, objective data will dominate).

    Time frame: 30 days

  3. Inpatient readmissions

    Inpatient hospital readmissions (number of events) will be assessed using health record review and self-report (in the event of inconsistencies, objective data will dominate).

    Time frame: through 3, 6, and 12 months

  4. Emergency department visits

    Emergency Department utilization (number of events) will be assessed via health record review and self-report (in the event of inconsistency, objective data will dominate).

    Time frame: through 3, 6, and 12 months

  5. Self-reported days of opioid use in the past 30 days

    Self-reported days of non-prescribed opioid use in the past 30 days will be assessed at each interview.

    Time frame: Baseline to 3-, 6-, and 12-months

  6. Opioid use

    Positive oral fluid test for non-prescribed opioids (e.g., fentanyl, heroin, etc.)

    Time frame: 3-, 6-, and 12-month follow-up

  7. Overdose events

    Overdose events will be assessed by self-report and health records (for non-fatal events) and death records (for fatal events)

    Time frame: through 3, 6, and 12 months

  8. Changes in Social Support from Baseline to Follow-up

    Social support will be measured using the Social Support Scale to determine the extent to which services influenced social support. It is a numeric scale from 0 to 100, with higher scores indicating greater social support.

    Time frame: Baseline to 3-, 6-, and 12-month follow-up

  9. Changes in Quality of Life from Baseline to Follow-up

    Quality of life will be measured via the World Health Organization Quality of Life instrument. It is a numeric scale with scores possible from 4-20, with higher scores indicating higher quality of life.

    Time frame: Baseline to 3-, 6-, and 12-month follow up

  10. Changes in Psychological distress from baseline

    Kessler Psychological Distress Scale will be used to assess how participants have been feeling (nervous, hopeless, restless, depressed, worthless, etc) during their last 30 days. It is a numeric scale with scores ranging from 0 to 24, with higher scores indicating greater psychological distress.

    Time frame: Baseline to 3-, 6- and 12-month follow-up

Other outcomes

  1. Rate of Patient-Directed Discharge

    Patient-directed discharge from the index hospitalization (i.e., "against medical advice") will be determined by health record review.

    Time frame: At discharge (assessed up to 12 months)

  2. Mortality

    Mortality will be tracked from participant monitoring and death records

    Time frame: through 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Gryczynski J, Nordeck CD, Welsh C, Mitchell SG, O'Grady KE, Schwartz RP. Preventing Hospital Readmission for Patients With Comorbid Substance Use Disorder : A Randomized Trial. Ann Intern Med. 2021 Jul;174(7):899-909. doi: 10.7326/M20-5475. Epub 2021 Apr 6. PubMed 33819055 ↗

Individual participant data

Plan to share: Yes — Participants will complete baseline surveys and follow-up study surveys, and some participants will complete qualitative interviews. The raw interview and survey data will be stored within a secure computing environment. Metadata, study protocols, data collection instruments (surveys, interview guides), codebooks, and de-identified versions of participant data will be preserved and shared as appropriate to facilitate interpretation and reuse.

Supporting information: Study protocol

Time frame: De-identified data and metadata will be deposited in a recognized repository such as the Inter-university Consortium for Political and Social Research (ICPSR) or another NIH-approved repository recommended by NINR. Once archived, datasets will be assigned persistent unique identifiers (such as DOIs) and indexed using repository tools and NIH-mandated descriptors to ensure they are findable and citable. De-identified data will be made available no later than the first publication of primary results or the end of the performance period, whichever comes first. Derived or summary datasets associated with publications will be shared with minimal delay. Shared data will remain available for at least five years following project completion, or longer if required by the repository or by NIH policy.

Access criteria: FRI is committed to facilitating access to study data for individual researchers or other stakeholders, upon reasonable request and execution of a data sharing and use agreement

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Jan 2029, 38 months after the start.

Of 465 non-industry interventional studies with no phase under Opioid-Related Disorders, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 47. This study's planned 38 months is above that.

Counting every sponsor, half of 496 studies reached it within 29 months; a quarter within 13 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2025
First posted
Dec 3, 2025
StartActual
Oct 27, 2025
Primary completionEst.
Jan 1, 2029
CompletionEst.
Aug 1, 2029
Last update
Dec 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07262190
Lead sponsor
Friends Research Institute, Inc.
Responsible party
Sponsor
First posted
Dec 3, 2025
Start date
Oct 27, 2025
Primary completion
Jan 1, 2029 (estimated)
Completion
Aug 1, 2029 (estimated)
Last update
Dec 3, 2025

Study contacts

Karen Alexander, PhD
Contact
kalexander@friendsresearch.org
2673983560
Jan Gryczynski, PhD
Contact
jgryczynski@friendsresearch.org
443-676-4219

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion